MCID: INV001
MIFTS: 48

Invasive Aspergillosis

Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Invasive Aspergillosis

MalaCards integrated aliases for Invasive Aspergillosis:

Name: Invasive Aspergillosis 12 15 70
Aspergillosis Invasive 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050073
UMLS 70 C0238013

Summaries for Invasive Aspergillosis

Disease Ontology : 12 An aspergillosis that is a serious fungal infection of the lung with pneumonia caused by Aspergillus, which spreads to other parts of the body through bloodstream in patients with acute leukemia and recipients of tissue transplants. Clinical symptoms include pulmonary nodules and hemorrhage.

MalaCards based summary : Invasive Aspergillosis, also known as aspergillosis invasive, is related to neutropenia and chronic granulomatous disease. An important gene associated with Invasive Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Caspofungin and Anidulafungin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and kidney, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Related Diseases for Invasive Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Invasive Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 587)
# Related Disease Score Top Affiliating Genes
1 neutropenia 31.5 MBL2 IL10 CXCL8 CSF3
2 chronic granulomatous disease 31.0 TLR5 IFNG CXCL8 CSF3
3 mucormycosis 31.0 IFNG CSF3 CLEC7A CCR6
4 aspergillosis 30.7 TLR6 TLR4 TLR2 TLR1 SFTPD PLG
5 acute graft versus host disease 30.7 NOD2 IL10 IFNG CSF3
6 bronchopneumonia 30.6 TLR4 IL10 CXCL8
7 allergic bronchopulmonary aspergillosis 30.6 SFTPD MBL2 IL10 IFNG
8 adult respiratory distress syndrome 30.6 SFTPD PLG IL10 CXCL8 CSF3
9 fungal infectious disease 30.5 TLR4 TLR2 IL10 IFNG CXCL8 CSF3
10 candidiasis 30.5 TLR4 TLR2 MBL2 IL10 IFNG CXCL8
11 fusariosis 30.5 CSF3 CLEC7A
12 toxic shock syndrome 30.4 TLR4 TLR2 IL10 IFNG CXCL8
13 endocarditis 30.4 TLR6 TLR2 IL10 IFNG CXCL8
14 endophthalmitis 30.4 TLR2 PLG CXCL8
15 thyroiditis 30.3 IL10 IFNG CXCL10
16 peritonitis 30.3 TLR4 TLR2 IL10 CXCL8
17 legionellosis 30.3 TLR5 TLR4 TLR2 CXCL8
18 pulmonary tuberculosis 30.3 TLR2 MBL2 IL10 IFNG
19 chronic graft versus host disease 30.2 IL10 IFNG
20 meningoencephalitis 30.1 IL10 CXCL10 CCR6
21 cryptococcosis 30.1 MBL2 IL10 IFNG CLEC7A CCR6
22 alcoholic hepatitis 30.1 TLR4 TLR2 IL10 IFNG CXCL8
23 optic neuritis 30.1 IL10 CXCL8 CXCL10
24 pneumocystosis 30.1 SFTPD CSF3 CLEC7A CCR6
25 pulmonary alveolar proteinosis 30.0 SFTPD IL10 CXCL8
26 osteomyelitis 30.0 TLR4 TLR2 NOD2 IL10 IFNG CXCL8
27 liver cirrhosis 30.0 TLR4 TLR2 SERPINA1 IL10 IFNG CXCL8
28 severe acute respiratory syndrome 30.0 TLR4 MBL2 IL10 IFNG CXCL8 CXCL10
29 respiratory failure 30.0 TLR4 SFTPD SERPINA1 IL10 CXCL8 CXCL10
30 covid-19 30.0 TLR4 CXCL8 CXCL10
31 hepatitis b 29.9 TLR4 TLR2 MBL2 IFNG CXCL8
32 conjunctivitis 29.9 TLR4 PLG IL10 IFNG CXCL8
33 severe combined immunodeficiency 29.9 IL4R IL10 IFNG CSF3
34 appendicitis 29.9 TLR4 IL10 IFNG CXCL8 CSF3
35 pulmonary sarcoidosis 29.9 SFTPD IFNG CCR6
36 common cold 29.9 IL10 CXCL8 CCR6
37 nervous system disease 29.9 TLR4 PLG IL10 IFNG CXCL8 CCR6
38 bronchiolitis obliterans 29.9 TLR4 SFTPD IL10 IFNG CXCL8
39 rhinitis 29.9 IL4R IL10 IFNG CXCL8
40 allergic rhinitis 29.8 IL4R IL10 IFNG CXCL8
41 sarcoidosis 1 29.8 SFTPD NOD2 IFNG CXCL10 CCR6
42 spondylitis 29.8 NOD2 IL10 IFNG CCR6
43 neuritis 29.8 IL10 IFNG CXCL8 CXCL10 CX3CR1
44 pyoderma 29.8 NOD2 CXCL8 CSF3 CCR6
45 pyoderma gangrenosum 29.8 NOD2 CXCL8 CSF3 CCR6
46 autoimmune disease 29.8 MBL2 IL10 IFNG CXCL8 CXCL10 CCR6
47 septic arthritis 29.7 TLR5 TLR4 TLR2 IFNG CXCL8
48 pulmonary disease, chronic obstructive 29.7 TLR2 SFTPD SERPINA1 IL10 CXCL8 CXCL10
49 vascular disease 29.7 TLR4 PLG IL10 IFNG CX3CR1 CSF3
50 bronchitis 29.7 TLR4 TLR2 SERPINA1 IL10 CXCL8 CXCL10

Graphical network of the top 20 diseases related to Invasive Aspergillosis:



Diseases related to Invasive Aspergillosis

Symptoms & Phenotypes for Invasive Aspergillosis

GenomeRNAi Phenotypes related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ARNT2 CCR6 CLEC7A CSF3 CXCL8 IL4R

MGI Mouse Phenotypes related to Invasive Aspergillosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 CCR6 CLEC7A CSF3 CX3CR1 CXCL10 IFNG
2 homeostasis/metabolism MP:0005376 10.2 ARNT2 CCR6 CLEC7A CX3CR1 CXCL10 IFNG
3 immune system MP:0005387 10.19 CCR6 CLEC7A CSF3 CX3CR1 CXCL10 IFNG
4 digestive/alimentary MP:0005381 10.1 CLEC7A CX3CR1 IFNG IL10 IL4R NOD2
5 mortality/aging MP:0010768 9.8 ARNT2 CLEC7A CX3CR1 CXCL10 IFNG IL10
6 liver/biliary system MP:0005370 9.76 ARNT2 IFNG IL10 IL4R PLG TLR2
7 respiratory system MP:0005388 9.28 CLEC7A IFNG IL10 IL4R PLG SFTPD

Drugs & Therapeutics for Invasive Aspergillosis

Drugs for Invasive Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
2
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
3
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
4
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
5
deoxycholic acid Approved Phase 3 83-44-3 222528
6
Isavuconazole Approved, Investigational Phase 3 241479-67-4
7 Gastrointestinal Agents Phase 3
8 Amphotericin B, deoxycholate drug combination Phase 3
9
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
10 Antiviral Agents Phase 2
11 interferons Phase 2
12 Interferon-gamma Phase 2
13 Anti-Bacterial Agents Phase 2
14 Antiparasitic Agents Phase 2
15 Liposomal amphotericin B Phase 2
16 Antiprotozoal Agents Phase 2
17 Amebicides Phase 2
18 Protective Agents Phase 2
19 Serine Proteinase Inhibitors Phase 2
20
protease inhibitors Phase 2
21 Cholesteryl sulfate Phase 2
22 HIV Protease Inhibitors Phase 2
23 Anti-Infective Agents, Local Phase 2
24
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
25
Rifampicin Approved Phase 1 13292-46-1 5381226 5458213
26
Fluconazole Approved, Investigational Phase 1 86386-73-4 3365
27 Psychotropic Drugs Phase 1
28 Hypnotics and Sedatives Phase 1
29 Anesthetics Phase 1
30 Neurotransmitter Agents Phase 1
31 GABA Modulators Phase 1
32 Anesthetics, Intravenous Phase 1
33 Anesthetics, General Phase 1
34 Anti-Anxiety Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
2 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Completed NCT03731169 Phase 4 Standard of Care
3 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
4 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
5 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
6 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
7 Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients Completed NCT00158730 Phase 3 AmBisome
8 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
9 A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) Completed NCT01782131 Phase 3 Posaconazole;Voriconazole;Placebo
10 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
11 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
12 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
13 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
14 Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients Recruiting NCT04707703 Phase 3 Isavuconazonium Injection [Cresemba];Placebo
15 A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients. Terminated NCT00836875 Phase 3 Voriconazole
16 A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years Withdrawn NCT01188759 Phase 3 Voriconazole;Anidulafungin;Voriconazole
17 A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis Completed NCT00404092 Phase 2 caspofungin
18 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
19 A Prospective, Randomized, Double-Blind, Multicenter Pilot Study Of The Safety And Efficacy Of Interferon Gamma- 1b (IFN-y 1b) Plus Voriconazole Versus Placebo Plus Voriconazole In The Treatment Of Invasive Aspergillosis And Other Filamentous Fungal Infections Completed NCT00059878 Phase 2 voriconazole
20 An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis Completed NCT00036166 Phase 2 FK463
21 A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to Less Than 18 Years With Invasive Aspergillosis Recruiting NCT04218851 Phase 2 Posaconazole IV;Posaconazole PFS;Posaconazole tablet
22 A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects Recruiting NCT03816176 Phase 2 Isavuconazonium sulfate;Isavuconazonium sulfate
23 An Open, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Population Pharmacokinetics of ABCD for Invasive Candidiasis and Invasive Aspergillosis Not yet recruiting NCT04225195 Phase 2 Amphotericin B cholesteryl sulfate complex for injection(ABCD)
24 A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis Terminated NCT00376337 Phase 2 Micafungin;Systemic antifungal therapy
25 A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients Terminated NCT03327727 Phase 2 Investigational Agent: VL-2397;Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
26 A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis Terminated NCT00047827 Phase 2 Micafungin;Liposomal Amphotericin B
27 An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia Withdrawn NCT02856178 Phase 1, Phase 2 F901318;Caspofungin
28 A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer Withdrawn NCT01207128 Phase 2 Voriconazole, micafungin
29 F901318 - A Phase I, Double-Blind, Placebo Controlled, Multiple Ascending Oral Dose Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects Completed NCT02737371 Phase 1 F901318 Dose level A oral;Placebo dose level A oral;F901318 Dose level B oral;Placebo dose level B oral;F901318 Dose level C oral;Placebo Dose level C oral
30 Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part B) Completed NCT01080651 Phase 1 Voriconazole
31 F901318 - A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects Completed NCT02342574 Phase 1 F901318;Placebo
32 F901318 - A Two Part Study Designed to Evaluate the Single and Multiple Dose Pharmacokinetics of an Immediate Release Tablet Formulation of F901318 Completed NCT02808741 Phase 1 F901318 SDD;F901318 IR;F901318 IR Fasting;F901318 IR Fed
33 An Open Label Study in Healthy Volunteers to Evaluate the Potential for Drug/Drug Interactions Between F901318 and Fluconazole Completed NCT02730442 Phase 1 F901318;Fluconazole
34 An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe Completed NCT02680808 Phase 1 Midazolam with F901318
35 F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects Completed NCT02394483 Phase 1 F901318 safety;F901318 tolerability;F901318 pharmacokinetics
36 F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects Completed NCT02142153 Phase 1 F901318;Placebo
37 A Phase I, Open Label Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Varying Oral Dosing Regimens for F901318 Completed NCT03340597 Phase 1 F901318
38 F901318 - A Phase I, Single Intravenous Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Subjects Withdrawn NCT03076905 Phase 1 F901318
39 An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects Withdrawn NCT03095547 Phase 1 cyclosporine A;Posaconazole;Pantoprazole;F901318;Tacrolimus
40 An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-F901318 Administered Via the Intravenous and Oral Routes to Healthy Male Subjects Withdrawn NCT02912026 Phase 1 IV F901318;Oral F901318
41 Novel Biomarkers for Invasive Aspergillosis Unknown status NCT03004092
42 An Evaluation of Sequential Computed Tomography of the Chest in Management of Invasive Pulmonal Aspergillosis in Neutropenic Patients With Haematological Malignancies Unknown status NCT02773342
43 An Observational Assessment of the Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome in the Setting of Invasive Aspergillosis in Patients With an Underlying Hematological Disorder Unknown status NCT01176071
44 CLARITY - Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy Unknown status NCT03221075
45 Early Diagnosis of Invasive Aspergillosis in a High Risk Group of Patients Using Serum and Bronchoalveolar Lavage Fluid Real Time PCR and Galactomannan ELISA Unknown status NCT00462657
46 ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS Unknown status NCT01742026
47 Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: an Italian Prospective Multicentre Study Unknown status NCT00838643
48 Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis in Hematological Patients Completed NCT03349931
49 Galactomannan Antigen and Real Time - PCR for Aspergillus DNA Detection in Bronchoalveolar Lavage. Application in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients Completed NCT01128907
50 Diagnosing Invasive Aspergillosis by PCR Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy Completed NCT01448226

Search NIH Clinical Center for Invasive Aspergillosis

Genetic Tests for Invasive Aspergillosis

Anatomical Context for Invasive Aspergillosis

MalaCards organs/tissues related to Invasive Aspergillosis:

40
Myeloid, Bone Marrow, Kidney, Brain, T Cells, Neutrophil, Endothelial

Publications for Invasive Aspergillosis

Articles related to Invasive Aspergillosis:

(show top 50) (show all 4254)
# Title Authors PMID Year
1
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 54 61
18946062 2008
2
Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4. 54 61
16951362 2006
3
TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. 54 61
16461792 2005
4
When should we use corticosteroids in severe community-acquired pneumonia? 61
33394726 2021
5
Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients. 61
32880845 2021
6
Pulmonary Aspergillosis: Spectrum of Disease. 61
33563417 2021
7
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. 61
33355949 2021
8
Diagnostic Performance of (1→3)-β-D-Glucan Alone and in Combination with Aspergillus PCR and Galactomannan in Serum of Pediatric Patients after Allogeneic Hematopoietic Stem Cell Transplantation. 61
33810069 2021
9
Pseudomembranous Tracheobronchitis With Severe Tracheal Stenosis and Masked Bronchial Obstruction. 61
33353810 2021
10
Assessment of the Role of 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults. 61
33709130 2021
11
Prevalence of Azole-Resistant Aspergillus fumigatus is Highly Associated with Azole Fungicide Residues in the Fields. 61
33544588 2021
12
Deep convolutional neural network: a novel approach for the detection of Aspergillus fungi via stereomicroscopy. 61
33779956 2021
13
Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization? 61
33495222 2021
14
Structural insights into novel mechanisms of inhibition of the major β-carbonic anhydrase CafB from the pathogenic fungus Aspergillus fumigatus. 61
33545350 2021
15
EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. 61
33709127 2021
16
The response regulator Skn7 of Aspergillus fumigatus is essential for the antifungal effect of fludioxonil. 61
33674651 2021
17
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. 61
33223114 2021
18
Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. 61
33709125 2021
19
Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination. 61
32837879 2021
20
Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. 61
33709129 2021
21
Diagnosis of central nervous system invasive aspergillosis in a liver transplant recipient using microbial cell-free next generation DNA sequencing. 61
33655668 2021
22
Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study. 61
33662543 2021
23
A Human Dectin-2 Deficiency Associated With Invasive Aspergillosis. 61
33733279 2021
24
Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single-centre study. 61
33683715 2021
25
Invasive Aspergillosis After Influenza and Other Viral Respiratory Infections Among Intensive Care Unit Patients in a Commercially Insured Population in the United States, 2013-2018. 61
33796602 2021
26
Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. 61
33761875 2021
27
Voriconazole Sequestration During Extracorporeal Membrane Oxygenation for Invasive Lung Aspergillosis: A Case Report. 61
33788798 2021
28
Respiratory Mycoses in COPD and Bronchiectasis. 61
33709335 2021
29
COVID-19-Associated Histoplasmosis in an AIDS Patient. 61
33156463 2021
30
Proven Fatal Invasive Aspergillosis in a Patient with COVID-19 and Staphylococcus aureus Pneumonia. 61
33808931 2021
31
American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. 61
33781516 2021
32
Performance, Correlation and Kinetic Profile of Circulating Serum Fungal Biomarkers of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. 61
33805751 2021
33
Invasive aspergillosis in critically ill patients: Review of Definitions and Diagnostic Approaches. 61
33760284 2021
34
Estimates of serious fungal infection burden in Côte d'Ivoire and country health profile. 61
33259981 2021
35
Endobronchial lipoma with tracheobronchial aspergillosis: A case report. 61
33725932 2021
36
Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU - A case report. 61
32837880 2021
37
Identification of Aspergillus species in human blood plasma by infrared spectroscopy and machine learning. 61
33307345 2021
38
Liver Transplantation in Patients With Pretransplant Aspergillus Colonization: Is It Safe to Proceed? 61
32301905 2021
39
Epidemiology of invasive fungal disease in haematologic patients. 61
33141969 2021
40
Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. 61
32837881 2021
41
A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment. 61
33619060 2021
42
Extensive Genetic Diversity and Widespread Azole Resistance in Greenhouse Populations of Aspergillus fumigatus in Yunnan, China. 61
33568450 2021
43
Insights in the molecular mechanisms of an azole stress adapted laboratory-generated Aspergillus fumigatus strain. 61
33550403 2021
44
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor. 61
33567487 2021
45
Antifungal Liposomes Directed by Dectin-2 Offer a Promising Therapeutic Option for Pulmonary Aspergillosis. 61
33622715 2021
46
Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis. 61
32780498 2021
47
All that glitters is not gold: a case report of a diffuse peritoneal aspergillosis. 61
32399543 2021
48
The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis. 61
33374010 2021
49
Molecular Epidemiology of Aspergillus fumigatus in Chronic Pulmonary Aspergillosis Patients. 61
33672698 2021
50
Performance of Existing Definitions and Tests for the Diagnosis of Invasive Fungal Diseases other than Invasive Candidiasis and Invasive Aspergillosis in Critically Ill, Adult Patients: A Systematic Review with Qualitative Evidence Synthesis. 61
33670864 2021

Variations for Invasive Aspergillosis

Expression for Invasive Aspergillosis

Search GEO for disease gene expression data for Invasive Aspergillosis.

Pathways for Invasive Aspergillosis

Pathways related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TLR6 TLR5 TLR4 TLR2 TLR1 SERPINA1
2
Show member pathways
13.66 TLR4 IL4R IL10 IFNG CXCL8 CXCL10
3
Show member pathways
13.36 TLR6 TLR5 TLR4 TLR2 TLR1 IL4R
4
Show member pathways
13.34 NOD2 IL4R IL10 IFNG CXCL8 CXCL10
5
Show member pathways
13.29 IL4R IL10 CXCL8 CXCL10 CX3CR1 CSF3
6
Show member pathways
13.19 TLR6 TLR5 TLR4 TLR2 TLR1 IL4R
7
Show member pathways
13.1 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
8
Show member pathways
12.82 TLR4 TLR2 PLG IFNG CXCL8 CXCL10
9
Show member pathways
12.75 TLR6 TLR5 TLR4 TLR2 TLR1 NOD2
10
Show member pathways
12.73 TLR6 TLR5 TLR4 TLR2 CXCL8
11
Show member pathways
12.68 TLR6 TLR5 TLR4 TLR2 TLR1
12
Show member pathways
12.61 TLR5 TLR4 TLR2 NOD2 IL4R IL10
13 12.59 TLR6 TLR2 TLR1 IL10 IFNG CXCL10
14
Show member pathways
12.58 TLR6 TLR5 TLR4 TLR2 TLR1
15
Show member pathways
12.41 TLR6 TLR5 TLR4 TLR2 TLR1
16
Show member pathways
12.39 IL4R IL10 IFNG CSF3
17
Show member pathways
12.36 TLR5 TLR2 IFNG CXCL8 CXCL10 CSF3
18
Show member pathways
12.34 IL10 CXCL8 CXCL10 CX3CR1 CCR6
19
Show member pathways
12.29 TLR6 TLR5 TLR4 TLR2 TLR1 CXCL8
20
Show member pathways
12.24 TLR4 TLR2 IL10 IFNG
21 12.2 TLR6 TLR5 TLR4 TLR2 TLR1 IFNG
22 12.14 TLR6 TLR4 TLR2 SFTPD MBL2 CLEC7A
23 12.11 TLR6 TLR4 TLR2 TLR1 NOD2 IL10
24
Show member pathways
12.07 TLR6 TLR5 TLR4 TLR2 TLR1
25 12.02 TLR4 IFNG CXCL8 CXCL10
26 12 IL10 IFNG CX3CR1 CSF3
27 11.96 TLR4 TLR2 IL10 IFNG CXCL8
28 11.88 TLR4 TLR2 IFNG CXCL8
29
Show member pathways
11.84 TLR4 CXCL8 CSF3
30 11.81 TLR6 TLR5 TLR4 TLR2 TLR1 CLEC7A
31 11.77 IL10 IFNG CCR6
32 11.74 TLR4 IL10 CXCL8
33 11.73 IL10 IFNG CX3CR1
34 11.71 TLR5 TLR4 TLR2 IL10 CCR6
35
Show member pathways
11.66 TLR6 TLR5 TLR4 TLR2 TLR1 IL4R
36 11.65 SERPINA1 CXCL8 CSF3
37 11.65 TLR5 TLR4 TLR2 CXCL8
38 11.58 IL10 CXCL8 CXCL10 CSF3
39 11.51 TLR4 TLR2 IFNG
40 11.5 TLR4 TLR2 IL10 IFNG CXCL8 CSF3
41 11.49 IL4R IL10 IFNG
42
Show member pathways
11.49 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
43
Show member pathways
11.38 TLR6 TLR5 TLR4 TLR2 TLR1 IL10
44 11.26 IL10 IFNG CSF3
45 11.19 TLR2 TLR1 IFNG

GO Terms for Invasive Aspergillosis

Cellular components related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 SFTPD SERPINA1 PLG MBL2 IL4R IL10
2 integral component of plasma membrane GO:0005887 9.92 TLR6 TLR5 TLR4 TLR2 TLR1 IL4R
3 extracellular space GO:0005615 9.65 SFTPD SERPINA1 PLG MBL2 IL4R IL10
4 phagocytic vesicle membrane GO:0030670 9.54 TLR6 TLR2 TLR1
5 cell surface GO:0009986 9.23 TLR4 TLR2 PLG NOD2 MBL2 CX3CR1
6 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 TLR6 TLR5 TLR4 TLR2 TLR1 IL4R
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TLR4 TLR2 NOD2 IL10 CXCL10 CSF3
3 immune system process GO:0002376 10.18 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
4 positive regulation of cell proliferation GO:0008284 10.17 NOD2 IFNG CXCL10 CSF3 CLEC7A ARNT2
5 positive regulation of gene expression GO:0010628 10.15 TLR6 TLR4 TLR2 IFNG CXCL8 CLEC7A
6 inflammatory response GO:0006954 10.13 TLR6 TLR5 TLR4 TLR2 TLR1 CXCL8
7 cytokine-mediated signaling pathway GO:0019221 10.09 IL4R IL10 CXCL8 CXCL10 CSF3
8 defense response to bacterium GO:0042742 10.09 TLR6 TLR5 TLR4 SFTPD NOD2 MBL2
9 innate immune response GO:0045087 10.07 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
10 response to lipopolysaccharide GO:0032496 10.04 TLR4 TLR2 NOD2 IL10 CXCL10
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.04 TLR6 TLR4 TLR2 NOD2 CX3CR1
12 chemotaxis GO:0006935 10.01 CXCL8 CXCL10 CX3CR1 CCR6
13 defense response GO:0006952 10.01 TLR1 NOD2 CXCL8 CXCL10
14 chemokine-mediated signaling pathway GO:0070098 9.95 CXCL8 CXCL10 CX3CR1 CCR6
15 positive regulation of interleukin-1 beta production GO:0032731 9.93 TLR4 NOD2 IFNG CLEC7A
16 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR4 TLR2 TLR1 NOD2 IFNG CLEC7A
17 positive regulation of phagocytosis GO:0050766 9.92 SFTPD NOD2 IFNG CLEC7A
18 calcium-mediated signaling GO:0019722 9.91 CXCL8 CX3CR1 CCR6
19 positive regulation of chemokine production GO:0032722 9.91 TLR4 TLR2 IL4R IFNG
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 TLR6 TLR5 TLR4 IFNG CLEC7A
21 negative regulation of tumor necrosis factor production GO:0032720 9.9 TLR4 NOD2 IL10
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TLR4 TLR2 NOD2
23 positive regulation of cytokine production GO:0001819 9.9 TLR5 IL10 IFNG
24 positive regulation of interleukin-10 production GO:0032733 9.9 TLR4 TLR2 NOD2 CLEC7A
25 microglial cell activation GO:0001774 9.89 TLR6 TLR2 TLR1 IFNG
26 positive regulation of interleukin-12 production GO:0032735 9.89 TLR4 TLR2 NOD2 IFNG CLEC7A
27 negative regulation of interferon-gamma production GO:0032689 9.88 TLR4 NOD2 IL10
28 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.88 TLR6 TLR4 NOD2 CLEC7A
29 positive regulation of macrophage activation GO:0043032 9.86 TLR6 TLR4 IL4R IL10
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.84 TLR4 TLR2 NOD2 IFNG
31 defense response to protozoan GO:0042832 9.83 IL4R IL10 CLEC7A
32 positive regulation of stress-activated MAPK cascade GO:0032874 9.83 TLR4 NOD2 CLEC7A
33 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.83 TLR6 TLR5 TLR4 TLR2 TLR1
34 cell activation GO:0001775 9.81 TLR6 TLR2 TLR1
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.8 TLR4 IL10 IFNG
36 response to molecule of bacterial origin GO:0002237 9.8 TLR2 IL10 CXCL8
37 positive regulation of interleukin-8 production GO:0032757 9.8 TLR5 TLR4 TLR2 TLR1 NOD2 CLEC7A
38 cellular response to bacterial lipopeptide GO:0071221 9.79 TLR6 TLR2 TLR1
39 positive regulation of signaling receptor activity GO:2000273 9.74 IL10 IFNG
40 macrophage activation GO:0042116 9.74 TLR4 TLR1
41 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.74 TLR6 TLR4
42 response to bacterial lipoprotein GO:0032493 9.74 TLR6 TLR2 TLR1
43 I-kappaB phosphorylation GO:0007252 9.73 TLR4 TLR2
44 cellular response to lipoteichoic acid GO:0071223 9.73 TLR4 TLR2
45 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.73 TLR6 TLR4
46 toll-like receptor signaling pathway GO:0002224 9.73 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
47 interleukin-1 beta production GO:0032611 9.72 TLR6 TLR4
48 cellular response to diacyl bacterial lipopeptide GO:0071726 9.72 TLR6 TLR2
49 positive regulation of killing of cells of other organism GO:0051712 9.72 IFNG CLEC7A
50 negative regulation of toll-like receptor 2 signaling pathway GO:0034136 9.71 TLR6 NOD2

Molecular functions related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.43 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
2 signaling receptor binding GO:0005102 9.89 TLR6 TLR4 PLG MBL2 CXCL10
3 transmembrane signaling receptor activity GO:0004888 9.8 TLR6 TLR5 TLR4 TLR2 TLR1
4 cytokine activity GO:0005125 9.77 IL10 IFNG CXCL8 CXCL10 CSF3
5 amyloid-beta binding GO:0001540 9.69 TLR6 TLR4 TLR2
6 signaling receptor activity GO:0038023 9.63 TLR6 TLR5 TLR4 TLR2 TLR1 CCR6
7 pattern recognition receptor activity GO:0038187 9.5 TLR2 NOD2 CLEC7A
8 lipopolysaccharide receptor activity GO:0001875 9.48 TLR4 TLR2
9 Toll-like receptor 2 binding GO:0035663 9.46 TLR6 TLR1
10 lipopeptide binding GO:0071723 9.43 TLR6 TLR2 TLR1
11 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.26 TLR6 TLR4 TLR2 TLR1
12 NAD(P)+ nucleosidase activity GO:0050135 8.92 TLR6 TLR4 TLR2 TLR1

Sources for Invasive Aspergillosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....